PEG10, One LncRNAs, A Possible Biomarker/Target for DLBCL--Dr. JiFeng Feng's Interview at CSMO 2015 by Oncology Practice Forum

Ji-Feng Feng, MD
Medical Oncology
Cancer Hospital of Jiangsu Province
Interviewed at CSMO 2015, Beijing
Photo: Oncology Practice Forum(肿瘤医学论坛)

Diffuse large B cell lymphoma (DLBCL)

Diffuse large B cell lymphoma (DLBCL) is the most common types of Non-Hodgkin's lymphoma.

It is of high morbidity, easy relapse, difficult cure and easy extensive metastasis characteristics.

Even with the improvement of systemic chemotherapy, target therapy and hematopoietic stem cell transplantation, some patients still easily to relapse after remission, develop drug resistance, thus make DLBCL difficult to treat.

Long non-coding RNAs (lncRNAs)

Long non-coding RNAs (lncRNAs) is a kind of more than 200 nt transcription length RNA molecules, incapable of translation. 80% of the Transcription genome is long non-coding RNAs, and they began to show important biological functions.

lncRNAs can participate in genomic imprinting, chromatin modification, transcription regulation, protein and other important signal transduction regulation.

LncRNAs regulation role, especially play an important role in the occurrence and development of tumor gradually draw more researchers' attention.

But, so far very little has known  about lncRNAs specific function involved in tumor occurrence and development , let alone research about lncRNAs function and mechanism in DLBCL.

PEG10

Through bioinformatics methods, we identified a set of lncRNAs expressed differently in DLBCL and non lymphoma tissue.

By analyzing clinical and basic research, we first discovered and confirmed lncRNAs PEG10 (PEG10) in the biological functions and clinical significance of DLBCL.

First of all, based on clinical studies(n = 107), we found that PEG10 tissue expression increased significantly in DLBCL; By building a ROC curve we can confirm PEG10 new molecular markers for DLBCL.

Then, through statistical analysis with clinical data, we revealed PEG10 expression is closely related to patient B symptoms,IPI score,CHOP (CHOP-like) treatment and use of rituximab.

Based on DLBCL patients' overall survival (OS) analysis, we found high PEG10 expression correlated to poor OS.

Furthermore, through cellular level research, we confirmed PEG10' expression significantly increased in DLBCL cell lines.

With the aid of molecular biology technology, such as RNA interference, we found that inhibition of PEG10 expression in lymphoma cells, can induce the apoptosis of lymphoma cells, thus inhibit cancer cells growth.

Our research shows that PEG10 can be a possible prognostic biomarker for DLBCL, and a therapeutic target.

References:

1. 冯继锋：长链非编码RNA在弥漫性大B细胞淋巴瘤中的价值研究 2015-07-06, 肿瘤医学论坛 公众微信号

2. Peng W. et al. Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity Clin Exp Med. 2015 Apr 12.